Dr. Rüdiger Jankowsky

Rüdiger Jankowsky, PhD, has been working in the biopharmaceutical industry since 1999. He had leadership positions in several companies in biopharmaceutical product development and business development, among them Scil, 4SC and Sandoz Biopharmaceuticals. Since 2014 he has been Managing Director/CEO in several startup and mid-size companies and has been responsible for the setup and leadership of international, interdisciplinary expert teams for drug development and business development.

Rüdiger’s area of expertise is biopharmaceuticals. He has comprehensive experience and oversees the entire process of biopharmaceutical development, from recombinant manufacturing to preclinical and clinical development, as well as regulatory approval processes for autoimmune and oncology drugs. He was decisively instrumental in the successful development, marketing authorization and licensing of several biopharmaceuticals and biosimilars.

In addition, Rüdiger has expert knowledge in the emerging field of digital health, he was CEO of a digital health company of the Swedish Sobi AB. He was responsible for the setup and leadership of an expert team for the development, regulatory approval, and market launch of software medical devices for patients with rare diseases.

Currently, Rüdiger supports the creation of a newly established biopharmaceutical company and advises several companies in strategic product development and business development.

Rüdiger is a biochemist by training and holds a diploma and a PhD in radiopharmaceutical chemistry from the Dresden University of Technology. After his PhD thesis he was Post Doc at the Institute of Molecular Biology and Biophysics at the Swiss Federal Institute of Technology in Zurich, Switzerland (ETH Zürich).